JP2005530484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530484A5 JP2005530484A5 JP2003565508A JP2003565508A JP2005530484A5 JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5 JP 2003565508 A JP2003565508 A JP 2003565508A JP 2003565508 A JP2003565508 A JP 2003565508A JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- angiogenesis
- albumin fusion
- albumin
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 claims 75
- 108010088751 Albumins Proteins 0.000 claims 75
- 108020001507 fusion proteins Proteins 0.000 claims 57
- 102000037865 fusion proteins Human genes 0.000 claims 57
- 230000033115 angiogenesis Effects 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 230000002401 inhibitory effect Effects 0.000 claims 28
- 238000000034 method Methods 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001419 dependent effect Effects 0.000 claims 11
- 238000001727 in vivo Methods 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010000050 Abdominal adhesions Diseases 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003732 Cat-scratch disease Diseases 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 230000002380 cytological effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002390 hyperplastic effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35554702P | 2002-02-07 | 2002-02-07 | |
| PCT/IB2003/000433 WO2003066085A1 (en) | 2002-02-07 | 2003-02-07 | Albumin-fused anti-angiogenesis peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530484A JP2005530484A (ja) | 2005-10-13 |
| JP2005530484A5 true JP2005530484A5 (enExample) | 2005-12-22 |
Family
ID=27734531
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565501A Pending JP2005516607A (ja) | 2002-02-07 | 2003-02-07 | Ｈｉｖ阻害タンパク質 |
| JP2003566175A Pending JP2005538932A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合クニッツドメインペプチド |
| JP2003565508A Pending JP2005530484A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合抗血管形成ペプチド |
| JP2009239593A Pending JP2010046076A (ja) | 2002-02-07 | 2009-10-16 | アルブミン融合クニッツドメインペプチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565501A Pending JP2005516607A (ja) | 2002-02-07 | 2003-02-07 | Ｈｉｖ阻害タンパク質 |
| JP2003566175A Pending JP2005538932A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合クニッツドメインペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009239593A Pending JP2010046076A (ja) | 2002-02-07 | 2009-10-16 | アルブミン融合クニッツドメインペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20060122374A1 (enExample) |
| EP (4) | EP1572930A4 (enExample) |
| JP (4) | JP2005516607A (enExample) |
| KR (4) | KR20040089608A (enExample) |
| CN (3) | CN1642567A (enExample) |
| AU (5) | AU2003244516A1 (enExample) |
| CA (3) | CA2475539A1 (enExample) |
| NZ (3) | NZ534492A (enExample) |
| WO (3) | WO2003066824A2 (enExample) |
| ZA (3) | ZA200406124B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| EP0737207B1 (en) | 1994-01-11 | 2004-09-22 | Dyax Corporation | Inhibitors of human plasmin derived from the kunitz domains |
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
| WO2004019968A1 (en) * | 2002-08-28 | 2004-03-11 | Dyax Corp. | Methods for preserving organs and tissues |
| WO2004056852A2 (en) | 2002-12-19 | 2004-07-08 | Nektar Therapeutics Al, Corp. | Cyanovirin variant-polymer conjugates |
| US6989369B2 (en) | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| JP2007525972A (ja) * | 2003-08-29 | 2007-09-13 | チルドレンズ メディカル センター コーポレーション | エンドスタチンのｎ末端からの抗血管新生性ペプチド |
| US9057061B2 (en) | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| US7744897B2 (en) | 2003-12-23 | 2010-06-29 | Dillon Susan B | Human immunodeficiency virus gp41 mimetibody polypeptides |
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| AU2011218732B2 (en) * | 2004-09-27 | 2013-07-04 | Takeda Pharmaceutical Company Limited | Kallikrein Inhibitors and Uses Thereof |
| ES2325344B1 (es) * | 2004-11-02 | 2010-06-09 | Univ Madrid Autonoma | Inhibidores de angiogenesis multifuncionales y multivalentes. |
| WO2006057997A2 (en) * | 2004-11-22 | 2006-06-01 | Dyax Corp. | Plasmin-inhibitory therapies |
| EP2330200B1 (en) | 2004-12-23 | 2017-04-05 | Albumedix A/S | Gene expression technique |
| EP1981519B1 (en) * | 2005-12-29 | 2017-12-27 | Dyax Corp. | Protease inhibition |
| CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| DK1854477T3 (en) | 2006-03-16 | 2016-11-28 | Dyax Corp | Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders |
| EP2423220B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| AR067584A1 (es) * | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos |
| EP2594583A1 (en) | 2007-08-08 | 2013-05-22 | Novozymes Biopharma DK A/S | Transferrin variants and conugates |
| WO2009026539A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| US9025330B2 (en) | 2007-09-30 | 2015-05-05 | Alcatel Lucent | Recirculating gas rack cooling architecture |
| WO2010049010A1 (en) | 2008-10-28 | 2010-05-06 | Murauski Uladzimir A | Methods and kits for detection of toxemia |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| CN102549012B (zh) | 2009-05-07 | 2015-07-01 | 诺维信生物制药丹麦公司 | 纯化白蛋白的方法 |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| CN101875693B (zh) * | 2010-01-22 | 2012-07-18 | 成都正能生物技术有限责任公司 | 具备抗血管生成活性的白蛋白变异体及其制备方法 |
| KR20130070576A (ko) * | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| CA2808675A1 (en) * | 2010-09-14 | 2012-03-22 | F. Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
| CN102453097A (zh) * | 2010-10-27 | 2012-05-16 | 上海科新生物技术股份有限公司 | 抑制血管新生的融合蛋白vf及药物组合物和应用 |
| WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| WO2012150319A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| US9290562B2 (en) * | 2011-08-17 | 2016-03-22 | The Regents Of The University Of Colorado | Transferrin-tumstatin fusion protein and methods for producing and using the same |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| CN102532326B (zh) * | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
| EP2817626B1 (en) | 2012-02-20 | 2017-09-27 | Uladzimir A. Murauski | Methods for detection of active malignancy |
| EP3330283A3 (en) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| DK2946206T3 (en) | 2013-01-20 | 2019-04-15 | Dyax Corp | EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS |
| AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
| EP2994483A4 (en) * | 2013-05-06 | 2017-02-08 | Cell Machines, Inc. | Methods and compositions related to large scale production of proteins |
| CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| DE102014112212A1 (de) | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| CN105440138A (zh) * | 2014-09-30 | 2016-03-30 | 复旦大学 | 一种长效内皮抑素融合蛋白的制备方法和用途 |
| CN108026214B (zh) | 2015-05-30 | 2021-03-02 | 基因组股份公司 | 乙烯基异构酶-脱水酶、烯醇脱水酶、芳樟醇脱水酶和/或巴豆醇脱水酶及其制备和使用 |
| CN104926946B (zh) * | 2015-07-13 | 2021-09-17 | 中国科学院广州生物医药与健康研究院 | 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用 |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| US10654912B2 (en) | 2015-09-08 | 2020-05-19 | Jcr Pharmaceuticals Co., Ltd. | Human serum albumin mutant |
| CN110317264B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物 |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| CN105646717B (zh) * | 2016-01-26 | 2020-06-09 | 复旦大学 | 一种长效hiv融合抑制剂及其应用 |
| EP4026908A1 (en) | 2017-06-20 | 2022-07-13 | Albumedix Ltd | Improved protein expression strains |
| WO2019032472A1 (en) * | 2017-08-08 | 2019-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | HIGH AFFINITY MODIFIED MATRIX INHIBITOR |
| JP2020532586A (ja) * | 2017-08-31 | 2020-11-12 | シンガポール ヘルス サービシーズ プライベート リミテッド | 網膜血管性疾患の処置のためのａｎｇｉｏ−３ |
| EP3684816B1 (en) * | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| PT3684786T (pt) | 2017-09-22 | 2024-10-30 | Centre Nat Rech Scient | Glicoproteína mutante do vírus da estomatite vesicular |
| CN109879969B (zh) * | 2017-12-06 | 2024-04-09 | 天士力生物医药股份有限公司 | 一种hm-3融合蛋白及其应用 |
| WO2020092448A1 (en) | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
| US11754570B2 (en) | 2019-04-16 | 2023-09-12 | Takeda Pharmaceutical Company Limited | Methods for quantitation of functional C1 esterase inhibitor (FC1-INH) |
| CN111995686B (zh) * | 2019-05-27 | 2022-06-14 | 兰州大学 | 一种具有抗血管生成活性的药物及其制备方法 |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN111494604B (zh) * | 2020-05-11 | 2022-05-06 | 中国药科大学 | 蓝藻抗病毒蛋白n在制备抗炎药物中的应用 |
| CN111560049B (zh) * | 2020-05-17 | 2022-05-17 | 浙江大学 | 两性离子多肽及其衍生物以及以其为基础的纳米药物 |
| WO2022007885A1 (zh) * | 2020-07-08 | 2022-01-13 | 南京师范大学 | 融合多肽和多肽二聚体及其用途 |
| CA3255646A1 (en) * | 2022-03-09 | 2023-09-14 | Immunofyx | N-TERMINAL FC CONJUGATED CANCER IMMUNOTHERAPY AGENTS |
| AU2024247601A1 (en) * | 2023-03-28 | 2025-10-23 | Nb Health Laboratory Co., Ltd. | Antibody, nucleic acid, cell and drug |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| IL327310A (en) | 2023-09-25 | 2026-05-01 | Kelonia Therapeutics Inc | Cancer treatment vehicles |
| CN117924430B (zh) * | 2024-03-22 | 2024-06-28 | 中国人民解放军军事科学院军事医学研究院 | 促进血小板生成的tpor结合肽 |
| CN120349425B (zh) * | 2025-04-21 | 2026-06-23 | 南方医科大学南方医院 | 一种重组融合蛋白及其在制备抗胃癌血管生成药物中的应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US355547A (en) | 1887-01-04 | mebcee | ||
| CA91311A (en) | 1904-11-15 | 1905-01-31 | The Canadian Westinghouse Company, Limited | Single phase alternating current motors |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
| US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| ES2052712T3 (es) | 1987-04-09 | 1994-07-16 | Delta Biotechnology Ltd | Vector de levadura. |
| ATE105767T1 (de) | 1987-07-08 | 1994-06-15 | Primtec | Nachdrucksteuerung und schliessen gestapelter formen eines mehrteiligen systems mit zeitlich auseinanderliegenden einspritzperioden. |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| ATE135045T1 (de) | 1988-07-23 | 1996-03-15 | Delta Biotechnology Ltd | Sekretorische leader-sequenzen |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| DE4244915C2 (de) | 1992-08-14 | 1998-12-03 | Widmar Prof Dr Tanner | DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| EP0737207B1 (en) * | 1994-01-11 | 2004-09-22 | Dyax Corporation | Inhibitors of human plasmin derived from the kunitz domains |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| CN1636594B (zh) * | 1994-04-26 | 2012-08-29 | 儿童医学中心公司 | 血管生成抑制素和用于抑制血管生成的方法 |
| GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
| US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6797488B1 (en) * | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US20030012792A1 (en) * | 1998-05-22 | 2003-01-16 | Holaday John W. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6087473A (en) | 1999-05-26 | 2000-07-11 | Zymogenetics, Inc. | Kunitz domain polypeptide and materials and methods for making it |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US20020048571A1 (en) * | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
| US20010056075A1 (en) * | 1999-07-19 | 2001-12-27 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
| AU2296301A (en) * | 1999-12-29 | 2001-07-09 | Zymogenetics Inc. | Kunitz domain polypeptide zkun10 |
| WO2001074980A2 (en) | 2000-04-03 | 2001-10-11 | Novozymes A/S | Enzyme tablets for cleaning improvement |
| US6946134B1 (en) * | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1197550A3 (en) * | 2000-08-25 | 2002-11-20 | Pfizer Products Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| US20020159992A1 (en) * | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| CA2841097A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| GB0329681D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| US9057061B2 (en) * | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| GB0329722D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| KR20130070576A (ko) * | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
-
2003
- 2003-02-07 US US10/503,836 patent/US20060122374A1/en not_active Abandoned
- 2003-02-07 CN CNA038069687A patent/CN1642567A/zh active Pending
- 2003-02-07 KR KR10-2004-7012254A patent/KR20040089608A/ko not_active Ceased
- 2003-02-07 KR KR10-2004-7012256A patent/KR20050002823A/ko not_active Ceased
- 2003-02-07 CA CA002475539A patent/CA2475539A1/en not_active Abandoned
- 2003-02-07 CA CA002485064A patent/CA2485064A1/en not_active Abandoned
- 2003-02-07 JP JP2003565501A patent/JP2005516607A/ja active Pending
- 2003-02-07 KR KR10-2004-7012255A patent/KR20040095217A/ko not_active Ceased
- 2003-02-07 NZ NZ534492A patent/NZ534492A/en not_active IP Right Cessation
- 2003-02-07 AU AU2003244516A patent/AU2003244516A1/en not_active Abandoned
- 2003-02-07 WO PCT/US2003/003616 patent/WO2003066824A2/en not_active Ceased
- 2003-02-07 NZ NZ534310A patent/NZ534310A/en not_active IP Right Cessation
- 2003-02-07 CN CN038076411A patent/CN1646154B/zh not_active Expired - Fee Related
- 2003-02-07 EP EP03737682A patent/EP1572930A4/en not_active Withdrawn
- 2003-02-07 EP EP03737416A patent/EP1471933A1/en not_active Withdrawn
- 2003-02-07 ZA ZA200406124A patent/ZA200406124B/xx unknown
- 2003-02-07 AU AU2003210885A patent/AU2003210885B2/en not_active Ceased
- 2003-02-07 WO PCT/IB2003/000434 patent/WO2003066078A1/en not_active Ceased
- 2003-02-07 AU AU2003244515A patent/AU2003244515A1/en not_active Abandoned
- 2003-02-07 JP JP2003566175A patent/JP2005538932A/ja active Pending
- 2003-02-07 CA CA002475382A patent/CA2475382A1/en not_active Abandoned
- 2003-02-07 EP EP09004575A patent/EP2090589A1/en not_active Withdrawn
- 2003-02-07 JP JP2003565508A patent/JP2005530484A/ja active Pending
- 2003-02-07 KR KR1020107028953A patent/KR20110014661A/ko not_active Ceased
- 2003-02-07 NZ NZ579419A patent/NZ579419A/en not_active IP Right Cessation
- 2003-02-07 WO PCT/IB2003/000433 patent/WO2003066085A1/en not_active Ceased
- 2003-02-07 EP EP03737417A patent/EP1471928A1/en not_active Ceased
- 2003-02-07 CN CNA038075164A patent/CN101166762A/zh active Pending
-
2004
- 2004-07-21 ZA ZA200405811A patent/ZA200405811B/en unknown
- 2004-07-21 ZA ZA200405813A patent/ZA200405813B/en unknown
-
2008
- 2008-12-23 AU AU2008264153A patent/AU2008264153A1/en not_active Abandoned
-
2009
- 2009-01-23 US US12/358,815 patent/US20090175893A1/en not_active Abandoned
- 2009-08-27 AU AU2009212820A patent/AU2009212820B2/en not_active Expired - Fee Related
- 2009-10-16 JP JP2009239593A patent/JP2010046076A/ja active Pending
-
2011
- 2011-10-31 US US13/285,727 patent/US20120263747A1/en not_active Abandoned
-
2013
- 2013-07-18 US US13/945,314 patent/US20140017273A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10774124B2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2005538932A5 (enExample) | ||
| ES2661310T3 (es) | Proteínas mirac | |
| JP4324325B2 (ja) | 突然変異化ｉｌ１３−をベースとするキメラ分子 | |
| JPS6156197A (ja) | リンホトキシンの細胞溶解活性を中和する抗体 | |
| JPH11240897A (ja) | ウロキナーゼレセプター活性のペプチドインヒビター | |
| JP2001518304A (ja) | アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 | |
| JP5208135B2 (ja) | 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物 | |
| JP5648637B2 (ja) | 血液脳関門障害改善剤 | |
| WO2002076486A2 (en) | Histidine-rich glycoprotein | |
| CN115028738A (zh) | 一种Fc融合蛋白双重靶向降解剂及应用 | |
| JPH10262668A (ja) | 血管形成誘導因子をコードするタンパク質コード配列を包含するｄｎａ配列 | |
| WO2005095443A1 (ja) | ペプチド改変を利用したドラッグデリバリーシステム | |
| JP2005534330A5 (enExample) | ||
| AU2013234365B2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2022501373A (ja) | 改善された第ｖｉｉｉ因子長期半減期凝固複合体に関連する方法および組成物 | |
| AU2016216675A1 (en) | Protease resistant mmutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1192845A (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1192845B (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1136211B (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| AU2002304352A1 (en) | Histidine-rich glycoprotein |